Prexasertib, a cell cycle checkpoint kinase 1 and 2 inhibitor, in BRCA wild-type recurrent high-grade serous ovarian cancer: a first-in-class proof-of-concept phase 2 study von Lee, Jung-Min, Nair, Jayakumar, Zimmer, Alexandra, Lipkowitz, Stanley, Annunziata, Christina M, Merino, Maria J, Swisher, Elizabeth M, Harrell, Maria I, Trepel, Jane B, Lee, Min-Jung, Bagheri, Mohammad H, Botesteanu, Dana-Adriana, Steinberg, Seth M, Minasian, Lori, Ekwede, Irene, Kohn, Elise C

Volltext

Activity of durvalumab plus olaparib in metastatic castration-resistant prostate cancer in men with and without DNA damage repair mutations von Karzai, Fatima, VanderWeele, David, Madan, Ravi A, Owens, Helen, Cordes, Lisa M, Hankin, Amy, Couvillon, Anna, Nichols, Erin, Bilusic, Marijo, Beshiri, Michael L, Kelly, Kathleen, Krishnasamy, Venkatesh, Lee, Sunmin, Lee, Min-Jung, Yuno, Akira, Trepel, Jane B, Merino, Maria J, Dittamore, Ryan, Marté, Jennifer, Donahue, Renee N, Schlom, Jeffrey, Killian, Keith J, Meltzer, Paul S, Steinberg, Seth M, Gulley, James L, Lee, Jung-Min, Dahut, William L

Volltext

The MAPK pathway across different malignancies: A new perspective von Burotto, Mauricio, Chiou, Victoria L., Lee, Jung‐Min, Kohn, Elise C.

Volltext

A Phase II Single Arm Pilot Study of the CHK1 Inhibitor Prexasertib (LY2606368) in BRCA Wild‐Type, Advanced Triple‐Negative Breast Cancer von Gatti‐Mays, Margaret E., Karzai, Fatima H., Soltani, Sanaz N., Zimmer, Alexandra, Green, Jeffrey E., Lee, Min‐Jung, Trepel, Jane B., Yuno, Akira, Lipkowitz, Stanley, Nair, Jayakumar, McCoy, Ann, Lee, Jung‐Min

Volltext

New strategies in ovarian cancer treatment von Lee, Jung‐Min, Minasian, Lori, Kohn, Elise C.

Volltext

A phase I study of the PD-L1 inhibitor, durvalumab, in combination with a PARP inhibitor, olaparib, and a VEGFR1-3 inhibitor, cediranib, in recurrent women's cancers with biomarker... von Zimmer, Alexandra S, Nichols, Erin, Cimino-Mathews, Ashley, Peer, Cody, Cao, Liang, Lee, Min-Jung, Kohn, Elise C, Annunziata, Christina M, Lipkowitz, Stanley, Trepel, Jane B, Sharma, Rajni, Mikkilineni, Lekha, Gatti-Mays, Margaret, Figg, William D, Houston, Nicole D, Lee, Jung-Min

Volltext

Recent Advances in Ammonia Combustion Technology in Thermal Power Generation System for Carbon Emission Reduction von Lee, Hookyung, Lee, Min-Jung

Volltext

Validity of Consumer-Based Physical Activity Monitors von LEE, JUNG-MIN, KIM, YOUNGWON, WELK, GREGORY J

Volltext

Tumour-elicited neutrophils engage mitochondrial metabolism to circumvent nutrient limitations and maintain immune suppression von Rice, Christopher M., Davies, Luke C., Subleski, Jeff J., Maio, Nunziata, Gonzalez-Cotto, Marieli, Andrews, Caroline, Patel, Nimit L., Palmieri, Erika M., Weiss, Jonathan M., Lee, Jung-Min, Annunziata, Christina M., Rouault, Tracey A., Durum, Scott K., McVicar, Daniel W.

Volltext

One fixed dosing of a poly(adenosine diphosphate ribose) polymerase inhibitor does not fit all von Lee, Jung‐Min, Liu, Joyce F.

Volltext

Genome-wide and high-density CRISPR-Cas9 screens identify point mutations in PARP1 causing PARP inhibitor resistance von Pettitt, Stephen J., Krastev, Dragomir B., Brandsma, Inger, Dréan, Amy, Song, Feifei, Aleksandrov, Radoslav, Harrell, Maria I., Menon, Malini, Brough, Rachel, Campbell, James, Frankum, Jessica, Ranes, Michael, Pemberton, Helen N., Rafiq, Rumana, Fenwick, Kerry, Swain, Amanda, Guettler, Sebastian, Lee, Jung-Min, Swisher, Elizabeth M., Stoynov, Stoyno, Yusa, Kosuke, Ashworth, Alan, Lord, Christopher J.

Volltext

Precisely printable and biocompatible silk fibroin bioink for digital light processing 3D printing von Kim, Soon Hee, Yeon, Yeung Kyu, Lee, Jung Min, Chao, Janet Ren, Lee, Young Jin, Seo, Ye Been, Sultan, Md. Tipu, Lee, Ok Joo, Lee, Ji Seung, Yoon, Sung-il, Hong, In-Sun, Khang, Gilson, Lee, Sang Jin, Yoo, James J., Park, Chan Hum

Volltext

The CHK1 inhibitor prexasertib in BRCA wild-type platinum-resistant recurrent high-grade serous ovarian carcinoma: a phase 2 trial von Giudice, Elena, Huang, Tzu-Ting, Nair, Jayakumar R., Zurcher, Grant, McCoy, Ann, Nousome, Darryl, Radke, Marc R., Swisher, Elizabeth M., Lipkowitz, Stanley, Ibanez, Kristen, Donohue, Duncan, Malys, Tyler, Lee, Min-Jung, Redd, Bernadette, Levy, Elliot, Rastogi, Shraddha, Sato, Nahoko, Trepel, Jane B., Lee, Jung-Min

Volltext

Notch signaling and efficacy of PD-1/PD-L1 blockade in relapsed small cell lung cancer von Roper, Nitin, Velez, Moises J., Chiappori, Alberto, Kim, Yoo Sun, Wei, Jun S., Sindiri, Sivasish, Takahashi, Nobuyuki, Mulford, Deborah, Kumar, Suresh, Ylaya, Kris, Trindade, Christopher, Manukyan, Irena, Brown, Anna-Leigh, Trepel, Jane B., Lee, Jung-Min, Hewitt, Stephen, Khan, Javed, Thomas, Anish

Volltext

Targeting the PI3K pathway and DNA damage response as a therapeutic strategy in ovarian cancer von Huang, Tzu-Ting, Lampert, Erika J., Coots, Cynthia, Lee, Jung-Min

Volltext

Designing Structural-Color Patterns Composed of Colloidal Arrays von Kim, Jong Bin, Lee, Seung Yeol, Lee, Jung Min, Kim, Shin-Hyun

Volltext

Comparison of Wearable Trackers' Ability to Estimate Sleep von Lee, Jung-Min, Byun, Wonwoo, Keill, Alyssa, Dinkel, Danae, Seo, Yaewon

Volltext

PARP Inhibitors in the Management of Ovarian Cancer: ASCO Guideline von Tew, William P, Lacchetti, Christina, Ellis, Annie, Maxian, Kathleen, Banerjee, Susana, Bookman, Michael, Jones, Monica Brown, Lee, Jung-Min, Lheureux, Stéphanie, Liu, Joyce F, Moore, Kathleen N, Muller, Carolyn, Rodriguez, Patricia, Walsh, Christine, Westin, Shannon N, Kohn, Elise C

Volltext

Update on PARP Inhibitors in Breast Cancer von Zimmer, Alexandra S., Gillard, Mitchell, Lipkowitz, Stanley, Lee, Jung-Min

Volltext

Clinical Evaluation and Biomarker Profiling of Hsp90 Inhibitors von Yuno, Akira, Lee, Min-Jung, Lee, Sunmin, Tomita, Yusuke, Rekhtman, David, Moore, Brittni, Trepel, Jane B.

Volltext